SRC and neoplasm: In high‐grade serous ovarian cancer (HGSOC), combination of MEK (AZD6244) and SRC (saracatinib) inhibitors overcomes EGFR‐mediated bypass of the RAS‐MAPK pathway and targets tumour initiating stem cells [61].